Literature DB >> 22554292

Des-γ-carboxyl prothrombin is associated with tumor angiogenesis in hepatocellular carcinoma.

Minoru Matsubara1, Hidenori Shiraha, Jyunro Kataoka, Masaya Iwamuro, Shigeru Horiguchi, Shin-ichi Nishina, Nobuyuki Takaoka, Masayuki Uemura, Akinobu Takaki, Shinichiro Nakamura, Yoshiyuki Kobayashi, Kazuhiro Nouso, Kazuhide Yamamoto.   

Abstract

BACKGROUND AND AIM: Hepatocellular carcinoma (HCC) is a hypervascular tumor, and angiogenesis plays an important role in its development. Previously, we demonstrated that des-γ-carboxyl prothrombin (DCP) promotes both cell proliferation and migration of human umbilical vein endothelial cells (HUVECs) by inducing the autophosphorylation of kinase insert domain receptor (KDR). In the present study, DCP-associated tumor angiogenesis was assessed by comparing hypovascular and common hypervascular HCC.
METHODS: The solitary HCCs of 827 patients were classified into two groups according to the tumor density at the arterial phase of a dynamic computed tomography scan; the initial clinical data of patients with the hyper- and hypovascular types were compared. The HCC tissues from 95 tumors were analyzed by immunohistochemical staining for DCP and phosphorylated KDR, and intratumoral microvessel density (MVD) was analyzed to evaluate microvessel angiogenesis.
RESULTS: The serum DCP levels (320 ± 3532 mAU/mL) and tumor size (18.4 ± 9.0 mm) of patients with hypervascular HCC were significantly greater than those with hypovascular HCC (38.7 ± 80 mAU/mL and 14.6 ± 5.2 mm, P < 0.001). Immunohistochemical analysis revealed that the expressions of DCP and phospho-KDR were significantly greater in hypervascular HCC (71.4% and 31.0%, respectively) than in hypovascular HCC (7.6% and 5.7%, respectively). Intratumoral MVD was significantly correlated with DCP (r = 0.48, P < 0.0001).
CONCLUSIONS: des-γ-carboxyl prothrombin production is associated with tumor angiogenesis in HCC.
© 2012 Journal of Gastroenterology and Hepatology Foundation and Wiley Publishing Asia Pty Ltd.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22554292     DOI: 10.1111/j.1440-1746.2012.07173.x

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  10 in total

Review 1.  Clinical application of protein induced by vitamin K antagonist-II as a biomarker in hepatocellular carcinoma.

Authors:  Hao Xing; Cunling Yan; Liming Cheng; Nianyue Wang; Shuyang Dai; Jianyong Yuan; Wenfeng Lu; Zhouchong Wang; Jun Han; Yijie Zheng; Tian Yang
Journal:  Tumour Biol       Date:  2016-10-13

Review 2.  Circulating biomarkers of hepatocellular carcinoma response after locoregional treatments: New insights.

Authors:  Maria Tampaki; Polyxeni P Doumba; Melanie Deutsch; John Koskinas
Journal:  World J Hepatol       Date:  2015-07-18

3.  Des-γ-carboxyprothrombin (DCP) and NX-DCP expressions and their relationship with clinicopathological features in hepatocellular carcinoma.

Authors:  Akiko Sumi; Jun Akiba; Sachiko Ogasawara; Masamichi Nakayama; Yoriko Nomura; Makiko Yasumoto; Sakiko Sanada; Osamu Nakashima; Toshi Abe; Hirohisa Yano
Journal:  PLoS One       Date:  2015-03-04       Impact factor: 3.240

Review 4.  Menahydroquinone-4 Prodrug: A Promising Candidate Anti-Hepatocellular Carcinoma Agent.

Authors:  Munechika Enjoji; Daisuke Watase; Kazuhisa Matsunaga; Mariko Kusuda; Nami Nagata-Akaho; Yoshiharu Karube; Jiro Takata
Journal:  Diseases       Date:  2015-07-22

5.  Development And Validation Of A Simple Model For Detection Of Early Hepatocellular Carcinoma In A Liver Cirrhosis Cohort.

Authors:  Tao Li; Hongguang Li; Aihua Wang; Xiaoyan Su; Jingfang Zhao; Yi Cui; Jun Liu; Jinhua Hu
Journal:  Cancer Manag Res       Date:  2019-11-05       Impact factor: 3.989

Review 6.  Proteomic Profiling and Artificial Intelligence for Hepatocellular Carcinoma Translational Medicine.

Authors:  Nurbubu T Moldogazieva; Innokenty M Mokhosoev; Sergey P Zavadskiy; Alexander A Terentiev
Journal:  Biomedicines       Date:  2021-02-06

7.  Evaluation of serum AFP and DCP levels in the diagnosis of early-stage HBV-related HCC under different backgrounds.

Authors:  Ting Song; Lili Wang; Ruopei Xin; Liping Zhang; Yun Tian
Journal:  J Int Med Res       Date:  2020-10       Impact factor: 1.671

8.  Clinical utility of serum fucosylated fraction of alpha-fetoprotein in the diagnostic of hepatocellular carcinoma: a comprehensive analysis with large sample size.

Authors:  Aibin Liu; Yanyan Li; Lin Shen; Liangfang Shen; Zhanzhan Li
Journal:  Aging (Albany NY)       Date:  2022-03-20       Impact factor: 5.682

9.  Identification of N-glycosylation in hepatocellular carcinoma patients' serum with a comparative proteomic approach.

Authors:  Yingnan Huang; Hao Wu; Ruyi Xue; Taotao Liu; Ling Dong; Jun Yao; Yang Zhang; Xizhong Shen
Journal:  PLoS One       Date:  2013-10-15       Impact factor: 3.240

10.  Antitumor Effects and Delivery Profiles of Menahydroquinone-4 Prodrugs with Ionic or Nonionic Promoiety to Hepatocellular Carcinoma Cells.

Authors:  Shuichi Setoguchi; Daisuke Watase; Kazuhisa Matsunaga; Hirofumi Yamakawa; Shotaro Goto; Kazuki Terada; Kenji Ohe; Munechika Enjoji; Yoshiharu Karube; Jiro Takata
Journal:  Molecules       Date:  2018-07-16       Impact factor: 4.411

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.